Here are the latest quarterly results of AUROBINDO PHARMA. For more details, see the AUROBINDO PHARMA financial fact sheet and AUROBINDO PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Mar-20* |
3
Jun-20* |
3
Sep-20* |
3
Dec-20* |
3
Mar-21* |
3
Jun-21* |
3
Sep-21* |
3
Dec-21* |
8-Qtr Chart Click to enlarge |
|
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | Rs m | 61,584 | 59,248 | 64,834 | 63,649 | 60,015 | 57,020 | 59,419 | 60,022 | |
Other income | Rs m | 326 | 1,156 | 538 | 1,334 | 781 | 1,099 | 966 | 650 | |
Turnover | Rs m | 61,910 | 60,404 | 65,372 | 64,983 | 60,796 | 58,119 | 60,385 | 60,672 | |
Expenses | Rs m | 48,422 | 46,674 | 50,506 | 49,963 | 47,268 | 44,926 | 47,552 | 49,860 | |
Gross profit | Rs m | 13,285 | 12,574 | 14,328 | 41,825 | 12,754 | 12,094 | 11,867 | 10,511 | |
Depreciation | Rs m | 2,324 | 2,555 | 2,573 | 2,765 | 2,660 | 2,797 | 2,942 | 2,991 | |
Interest | Rs m | 318 | 211 | 157 | 195 | 182 | 129 | 104 | 161 | |
Profit before tax | Rs m | 10,968 | 10,964 | 12,135 | 40,199 | 10,692 | 10,267 | 9,787 | 8,009 | |
Tax | Rs m | 2,144 | 3,012 | 3,857 | 10,575 | 2,597 | 2,477 | 2,709 | 1,895 | |
Profit after tax | Rs m | 8,825 | 7,952 | 8,278 | 29,624 | 8,096 | 7,790 | 7,078 | 6,114 | |
Gross profit margin | % | 21.6 | 21.2 | 22.1 | 65.7 | 21.3 | 21.2 | 20.0 | 17.5 | |
Effective tax rate | % | 19.5 | 27.5 | 31.8 | 26.3 | 24.3 | 24.1 | 27.7 | 23.7 | |
Net profit margin | % | 14.3 | 13.4 | 12.8 | 46.5 | 13.5 | 13.7 | 11.9 | 10.2 | |
Diluted EPS | Rs | 15.1 | 13.6 | 14.1 | 50.6 | 13.8 | 13.3 | 12.1 | 10.4 | |
Diluted EPS (TTM) | Rs | 48.8 | 51.6 | 54.8 | 93.3 | 92.1 | 91.8 | 89.7 | 49.6 | |
![]() |
Indian share markets rose today as easing bets about aggressive interest rate hikes by central banks lifted sentiment.
Here's why the company sold its business unit to Eugia Pharma Specialities.
Aurobindo Pharma shares fell nearly 4% after quarterly earnings disappoint.
Here's why Divi's Lab's stock fell over 10% in two days.
For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.
During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.
More Views on NewsWe are just two months into 2022 and several penny stocks that we track have already surged 5x.
Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.
A step-by-step method to pick the best penny stocks for the long term.
These penny stocks can become future multibaggers. Watch out for them.
Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?
More